Human CD106 ELISA Set
| Code | Size | Price |
|---|
| 851.660.005 | 5 x 96 | £333.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Further Information
Antigen Synonyms:
VCAM-1
Assay Range:
1.56-50 ng/ml
Cross reaction:
No cross reactivity with other human adhesion molecules
Description:
Diaclone ELISA Sets include capture and biotinylated detection antibody one standard per plate Streptavidin-HRP TMB and detailed procedure including buffer composition.
Detection Target:
CD106 / VCAM-1
Incubation:
From sample to end 1h45
Reactivity:
Human
Research Area:
Cell Adhesion
Sample Size:
100 µl
Sample Types:
Serum Plasma Cell culture supernatant
Sensitivity:
0.6 ng/ml
Specificity:
Recognizes both natural and recombinant human soluble VCAM-1
References
- Raberin A. et al. Oxid Med Cell Longev. 2020; 2020: 1315471. . Role of Gender and Physical Activity Level on Cardiovascular Risk Factors and Biomarkers of Oxidative Stress in the Elderly. https://pubmed.ncbi.nlm.nih.gov/32655757/
- Hemelaar M. et al. Hum Reprod.2006; 21(6): 1635-42.. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. https://www.ncbi.nlm.nih.gov/pubmed/16501036
- Stegenga M. E. et al. Blood: blood-2007-11-121723. Hyperglycemia enhances coagulation and reduces neutrophil degranulation whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. https://www.ncbi.nlm.nih.gov/pubmed/18316629
- Tripette J. et al.Br. J. Sports Med.2010;44(4): 232-237. Patterns of exercise-related inflammatory response in sickle cell trait carriers. https://www.ncbi.nlm.nih.gov/pubmed/18499764
Related Products
| Product Name | Product Code | Supplier | Accessory pack for ELISA set | 858.000.005 | Diaclone | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|